1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I,
Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN
Estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin 71: 209‑249, 2021.
2. Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R
and Polkowski WP: Gastric cancer: Epidemiology, prevention,
classification and treatment. Cancer Manag Res 10: 239‑248, 2018.
3. Takahashi T, Saikawa Y and Kitagawa Y: Gastric cancer: Current
status of diagnosis and treatment. Cancers (Basel) 5: 48‑63, 2013.
4. Sugano K: Screening of gastric cancer in Asia. Best Pract Res
Clin Gastroenterol 29: 895‑905, 2015.
5. Japanese Gastric Cancer Association: Japanese gastric cancer
treatment guidelines 2014 (ver. 4). Gastric Cancer 20: 1‑19, 2017.
6. Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC,
Ho J and Unverzagt S: Chemotherapy for advanced gastric
cancer. Cochrane Database Syst Rev 8: CD004064, 2017.
7. Pan D: Hippo signaling in organ size control. Genes Dev 21:
886‑897, 2007.
8. Zanconato F, Cordenonsi M and Piccolo S: YAP/TAZ at the roots
of cancer. Cancer Cell 29: 783‑803, 2016
9. Zhang J, Xu ZP, Yang YC, Zhu JS, Zhou Z and Chen WX: Expression
of yes‑associated protein in gastric adenocarcinoma and inhibitory
effects of its knockdown on gastric cancer cell proliferation and
metastasis. Int J Immunopathol Pharmacol 25: 583‑590, 2012.
10. Zanconato F and Piccolo S: Eradicating tumor drug resistance at
its YAP ‑biomechanical roots. EMBO J 35: 459‑461, 2016.
11. Zhou Y, Wang Y, Zhou W, Chen T, Wu Q, Chutturghoon VK,
Lin B, Geng L, Yang Z, Zhou L and Zheng S: YAP promotes
multi‑drug resistance and inhibits autophagy‑related cell death
in hepatocellular carcinoma via the RAC1‑ROS‑mTOR pathway.
Cancer Cell Int 19: 179, 2019.
12. Song J, Xie LX, Zhang XY, Hu P, Long MF, Xiong F, Huang J
and Ye XQ: Role of YAP in lung cancer resistance to cisplatin.
Oncol Lett 16: 3949‑3954, 2018.
13. Song R, Gu D, Zhang L, Zhang X, Yu B, Liu B and Xie J:
Functional significance of Hippo/YAP signaling for drug resis‑
tance in colorectal cancer. Mol Carcinog 57: 1608‑1615, 2018.
14. Lu T, Sun L and Zhu X: Yes‑associated protein enhances prolif‑
eration and attenuates sensitivity to cisplatin in human gastric
cancer cells. Biomed Pharmacother 105: 1269‑1275, 2018.
15. Shi J, Li F, Yao X, Mou T, Xu Z, Han Z, Chen S, Li W, Yu J,
Qi X, et al: The HER4‑YAP1 axis promotes trastuzumab resis‑
tance in HER2‑positive gastric cancer by inducing epithelial and
mesenchymal transition. Oncogene 37: 3022‑3038, 2018.
16. Hu X, Xin Y, Xiao Y and Zhao J: Overexpression of YAP1 is corre‑
lated with progression, metastasis and poor prognosis in patients
with gastric carcinoma. Pathol Oncol Res 20: 805‑811, 2014.
17. Yue G, Sun X, Gimenez‑Capitan A, Shen J, Yu L, Teixido C, Guan W,
Rosell R, Liu B and Wei J: TAZ is highly expressed in gastric signet
ring cell carcinoma. Biomed Res Int 2014: 393064, 2014.
18. Cruess AF, Zlateva G, Pleil AM and Wirostko B: Photodynamic
therapy with verteporfin in age‑related macular degeneration: A
systematic review of efficacy, safety, treatment modifications and
pharmacoeconomic properties. Acta Ophthalmol 87: 118‑132,
2009.
11
19. Mae Y, Kanda T, Sugihara T, Takata T, Kinoshita H, Sakaguchi T,
Hasegawa T, Tarumoto R, Edano M, Kurumi H, et al:
Verteporfin‑photodynamic therapy is effective on gastric cancer
cells. Mol Clin Oncol 13: 10, 2020.
20. Dasari VR, Mazack V, Feng W, Nash J, Carey DJ and Gogoi R:
Verteporfin exhibits YAP‑independent anti‑proliferative and
cytotoxic effects in endometrial cancer cells. Oncotarget 8:
28628‑28640, 2017.
21. Al‑Moujahed A, Brodowska K, Stryjewski TP, Efstathiou NE,
Vasilikos I, Cichy J, Miller JW, Gragoudas E and Vavvas DG:
Verteporfin inhibits growth of human glioma in vitro without
light activation. Sci Rep 7: 7602, 2017.
22. Dong L, Lin F, Wu W, Liu Y and Huang W: Verteporfin inhibits
YAP‑induced bladder cancer cell growth and invasion via Hippo
signaling pathway. Int J Med Sci 15: 645‑652, 2018.
23. Livak KJ and Schmittgen TD: Analysis of relative gene expres‑
sion data using real‑time quantitative PCR and the 2(‑Delta Delta
C(T)) method. Methods 25: 402‑408, 2001.
24. Schneider CA, Rasband WS and Eliceiri KW: NIH image to
imageJ: 25 years of image analysis. Nat Methods 9: 671‑675,
2012.
25. Huggett MT, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M,
Kent E, Bown SG, Hasan T, Pogue BW and Pereira SP: Phase I/II
study of verteporfin photodynamic therapy in locally advanced
pancreatic cancer. Br J Cancer 110: 1698‑1704, 2014.
26. B r o d ow s k a K , A l ‑ M o uj a h e d A , M a r m a l i d o u A,
Meyer Zu Horste M, Cichy J, Miller JW, Gragoudas E and
Vavvas DG: The clinically used photosensitizer Verteporfin
(VP) inhibits YAP‑TEAD and human retinoblastoma cell growth
in vitro without light activation. Exp Eye Res 124: 67‑73, 2014.
27. Feng J, Gou J, Jia J, Yi T, Cui T and Li Z: Verteporfin, a suppressor
of YAP‑TEAD complex, presents promising antitumor proper‑
ties on ovarian cancer. Onco Targets Ther 9: 5371‑5381, 2016.
28. Wang C, Zhu X, Feng W, Yu Y, Jeong K, Guo W, Lu Y and
Mills GB: Verteporfin inhibits YAP function through up‑regu‑
lating 14‑3‑3σ sequestering YAP in the cytoplasm. Am J Cancer
Res 6: 27‑37, 2015.
29. Kang W, Tong JH, Chan AW, Lee TL, Lung RW, Leung PP,
So KK, Wu K, Fan D, Yu J, et al: Yes‑associated protein 1
exhibits oncogenic property in gastric cancer and its nuclear
accumulation associates with poor prognosis. Clin Cancer
Res 17: 2130‑2139, 2011.
30. Li P, Sun D, Li X, He Y, Li W, Zhao J, Wang Y, Wang H and
Xin Y: Elevated expression of Nodal and YAP1 is associated
with poor prognosis of gastric adenocarcinoma. J Cancer Res
Clin Oncol 142: 1765‑1773, 2016.
31. Hong SA, Son MW, Cho J, Jang SH, Lee HJ, Lee JH, Cho HD,
Oh MH and Lee MS: Low angiomotin‑p130 with concomitant
high Yes‑associated protein 1 expression is associated with
adverse prognosis of advanced gastric cancer. APMIS 125:
996‑1006, 2017.
32. Huang S, Zhu L, Cao Y, Li L, Xie Y, Deng J and Xiong J:
Significant association of YAP1 and HSPC111 proteins with
poor prognosis in Chinese gastric cancer patients. Oncotarget 8:
80303‑80314, 2017.
33. Zhang L, Song X, Li X, Wu C and Jiang J: Yes‑Associated protein
1 as a novel prognostic biomarker for gastrointestinal cancer: A
meta‑analysis. Biomed Res Int 2018: 4039173, 2018.
34. Choi W, Kim J, Park J, Lee DH, Hwang D, Kim JH, Ashktorab H,
Smoot D, Kim SY, Choi C, et al: YAP/TAZ initiates gastric
tumorigenesis via upregulation of MYC. Cancer Res 78:
3306‑3320, 2018.
35. Morin‑Kensicki EM, Boone BN, Howell M, Stonebraker JR,
Teed J, Alb JG, Magnuson TR, O'Neal W and Milgram SL:
Defects in yolk sac vasculogenesis, chorioallantoic fusion, and
embryonic axis elongation in mice with targeted disruption of
Yap65. Mol Cell Biol 26: 77‑87, 2006.
36. Tian Y, Kolb R, Hong JH, Carroll J, Li D, You J, Bronson R,
Yaffe MB, Zhou J and Benjamin T: TAZ promotes PC2 degra‑
dation through a SCFbeta‑Trcp E3 ligase complex. Mol Cell
Biol 27: 6383‑6395, 2007.
37. Plouffe SW, Lin KC, Moore JL III, Tan FE, Ma S, Ye Z, Qiu Y,
Ren B and Guan KL: The Hippo pathway effector proteins YAP
and TAZ have both distinct and overlapping functions in the cell.
J Biol Chem 293: 11230‑11240, 2018.
38. Hayashi H, Higashi T, Yokoyama N, Kaida T, Sakamoto K,
Fukushima Y, Ishimoto T, Kuroki H, Nitta H, Hashimoto D, et al:
An imbalance in TAZ and YAP expression in hepatocellular
carcinoma confers cancer stem cell‑like behaviors contributing
to disease progression. Cancer Res 75: 4985‑4997, 2015.
12
HASEGAWA et al: VERTEPORFIN INHIBITS YAP‑ AND TAZ‑DOMINANT GASTRIC CANCER CELLS
39. Finch‑Edmondson ML, Strauss RP, Passman AM, Sudol M,
Yeoh GC and Callus BA: TAZ protein accumulation is nega‑
tively regulated by YAP abundance in mammalian cells. J Biol
Chem 290: 27928‑27938, 2015.
40. Altieri DC: Survivin, versatile modulation of cell division and
apoptosis in cancer. Oncogene 22: 8581‑8589, 2003.
41. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N,
Oltersdorf T and Reed JC: IAP‑family protein survivin inhibits
caspase activity and apoptosis induced by Fas (CD95), Bax,
caspases, and anti‑cancer drugs. Cancer Res 58: 5315‑5320, 1998.
42. Cerda‑Opazo P, Valenzuela‑Valderrama M, Wichmann I,
Rodríguez A, Contreras‑Reyes D, Fernández EA, CarrascoAviño G, Corvalán AH and Quest AFG: Inverse expression of
survivin and reprimo correlates with poor patient prognosis in
gastric cancer. Oncotarget 9: 12853‑12867, 2018.
43. Bertazza L, Mocellin S, Marchet A, Pilati P, Gabrieli J, Scalerta R
and Nitti D: Survivin gene levels in the peripheral blood of
patients with gastric cancer independently predict survival.
J Transl Med 7: 111, 2009.
44. Zhang J, Zhu Z, Sun Z, Sun X, Wang Z and Xu H: Survivin gene
expression increases gastric cancer cell lymphatic metastasis by
up‑regulating vascular endothelial growth factor‑C expression
levels. Mol Med Rep 9: 600‑606, 2014.
45. Da C, Xin Y, Zhao J and Luo X: Significance and relationship
between Yes‑associated protein and survivin expression in gastric
carcinoma and precancerous lesions. World J Gastroenterol 15:
4055‑4061, 2009.
46. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM,
Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and
in vitro: Vasculogenic mimicry. Am J Pathol 155: 739‑752,
1999.
47. Zhang S, Zhang D and Sun B: Vasculogenic mimicry: Current
status and future prospects. Cancer Lett 254: 157‑164, 2007.
48. Sun J, Sun B, Sun R, Zhu D, Zhao X, Zhang Y, Dong X, Che N,
Li J, Liu F, et al: HMGA2 promotes vasculogenic mimicry and
tumor aggressiveness by up‑regulating Twist1 in gastric carci‑
noma. Sci Rep 7: 2229, 2017.
49. Bora‑Singhal N, Nguyen J, Schaal C, Perumal D, Singh S,
Coppola D and Chellappan S: YAP1 regulates OCT4 activity and
SOX2 expression to facilitate self‑renewal and vascular mimicry
of stem‑like cells. Stem Cells 33: 1705‑1718, 2015.
50. Wei H, Wang F, Wang Y, Li T, Xiu P, Zhong J, Sun X and
Li J: Verteporfin suppresses cell survival, angiogenesis and
vasculogenic mimicry of pancreatic ductal adenocarcinoma via
disrupting the YAP‑TEAD complex. Cancer Sci 108: 478‑487,
2017.
51. Kim HS, Won YJ, Shim JH, Kim HJ, Kim J, Hong HN and
Kim BS: Morphological characteristics of vasculogenic mimicry
and its correlation with EphA2 expression in gastric adenocarci‑
noma. Sci Rep 9: 3414, 2019.
52. Kang MH, Jeong GS, Smoot DT, Ashktorab H, Hwang CM,
Kim BS, Kim HS and Park YY: Verteporfin inhibits gastric
cancer cell growth by suppressing adhesion molecule FAT1.
Oncotarget 8: 98887‑98897, 2017.
53. Xiong J, Wang S, Chen T, Shu X, Mo X, Chang G, Chen JJ,
Li C, Luo H and Lee JD: Verteporfin blocks Clusterin which is
required for survival of gastric cancer stem cell by modulating
HSP90 function. Int J Biol Sci 15: 312‑324, 2019.
54. Giraud J, Molina‑Castro S, Seeneevassen L, Sifré E, Izotte J,
Tiffon C, Staedel C, Boeuf H, Fernandez S, Barthelemy P, et al:
Verteporfin targeting YAP1/TAZ‑TEAD transcriptional activity
inhibits the tumorigenic properties of gastric cancer stem cells.
Int J Cancer 146: 2255‑2267, 2020.
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0
International (CC BY-NC-ND 4.0) License.
...
論文の公開元へ
